The Synairgen share price: here’s why I’d buy and hold this stock

The Synairgen share price has gained over 800% in the past year. With a potentially effective Covid treatment, I think this stock is a long-term opportunity.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Synairgen (LSE: SNG) share price delivered a great return on investment last year. The shares started the year at 6.34p each and ended it at 153p. The spike in price was caused by the firm’s development of a Covid-19 treatment called SNG001 and its early success. It received positive results from its phase 2 study that started in March 2020.

So far this year, Synairgen shares are up 3.7% and the 12-month return is around 838%. That said, at early Tuesday afternoon’s price of just under 157p, the stock is well below its record level of 246p from August 2020. But maybe that’s an opportunity for me. I see Synairgen as a long-term ‘buy’ as it seems Covid is here to stay, despite vaccine success.

Synairgen’s Covid-19 treatment

Synairgen was founded in 2003 by three professors who had a vision of creating a respiratory drug discovery-and-development company. But with a market capitalisation of just around £315m, it’s still a fairly small business. It has only three proprietary drug programs in its pipeline, with the most eye-catching being SNG001, its treatment for Covid-19 patients.

The company clearly differs from giant pharmaceutical companies such as Pfizer, Moderna, and AstraZeneca. They’ve focused on developing a Covid-19 vaccine, by targeting coronavirus patients instead. Synairgen has recently commenced a phase 3 trial, which is being tested in approximately 20 countries and includes 610 Covid-19 patients. 

Vaccines aren’t 100% effective and not everyone will take them. So, I firmly believe that the treatment, if approved, could potentially reduce the risk of this pandemic in the long term.

Synairgen share price outlook

That would be good news. But obviously, it’s a challenge to predict what the future holds for the company right now. The world is in wait-and-see mode, and the lasting impact of the coronavirus pandemic is not yet apparent in the global economy. But here’s why I think the business is a good buy right now — and it isn’t just because the Synairgen share price is far from its all-time high. Right now, there’s no effective treatment for Covid-19 patients. The world really needs a treatment for the disease as vaccines probably won’t eliminate it on their own.

When I look ahead, this is a key reason why I believe Synairgen is a good stock to hold for the long term. Of course, even though the price has fallen recently, the spike in the Synairgen share price over the last year makes this stock risky. And the share price is likely to drop if the company fails to achieve its targets.

But overall, I’m optimistic about the outlook. And even though Synairgen is seen as a ‘Covid-19 stock’, it’s not a one-trick pony. Its BioBank platform technology, for instance, is quite impressive. It should help Synairgen discover and develop novel therapies for respiratory diseases in general. Additionally, its pipeline portfolio includes inhaled interferon for asthma patients and a treatment for COPD.

As such, I’m going to add the stock to my portfolio today, especially following the drop in the Synairgen share price in the past week. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Tom Chen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Surely, the Rolls-Royce share price can’t go any higher in 2025?

The Rolls-Royce share price was the best performer on the FTSE 100 in 2023 and so far in 2024. Dr…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

Here’s how an investor could start buying shares with £100 in January

Our writer explains some of the things he thinks investors on a limited budget should consider before they start buying…

Read more »

Investing Articles

Forget FTSE 100 airlines! I think shares in this company offer better value to consider

Stephen Wright thinks value investors looking for shares to buy should include aircraft leasing company Aercap. But is now the…

Read more »

Investing Articles

Are Rolls-Royce shares undervalued heading into 2025?

As the new year approaches, Rolls-Royce shares are the top holding of a US fund recommended by Warren Buffett. But…

Read more »

Investing Articles

£20k in a high-interest savings account? It could be earning more passive income in stocks

Millions of us want a passive income, but a high-interest savings account might not be the best way to do…

Read more »

Investing Articles

3 tried and tested ways to earn passive income in 2025

Our writer examines the latest market trends and economic forecasts to uncover three great ways to earn passive income in…

Read more »

Investing Articles

Here’s what £10k invested in the FTSE 100 at the start of 2024 would be worth today

Last week's dip gives the wrong impression of the FTSE 100, which has had a pretty solid year once dividends…

Read more »

Investing Articles

UK REITs: a once-in-a-decade passive income opportunity?

As dividend yields hit 10-year highs, Stephen Wright thinks real estate investment trusts could be a great place to consider…

Read more »